985 related articles for article (PubMed ID: 29584808)
1. Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.
Adão R; Mendes-Ferreira P; Santos-Ribeiro D; Maia-Rocha C; Pimentel LD; Monteiro-Pinto C; Mulvaney EP; Reid HM; Kinsella BT; Potus F; Breuils-Bonnet S; Rademaker MT; Provencher S; Bonnet S; Leite-Moreira AF; Brás-Silva C
Cardiovasc Res; 2018 Jul; 114(8):1165-1177. PubMed ID: 29584808
[TBL] [Abstract][Full Text] [Related]
2. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane Improves Redox Homeostasis and Right Ventricular Contractility in a Model of Pulmonary Hypertension.
Conzatti A; Colombo R; Siqueira R; Campos-Carraro C; Turck P; Luz de Castro A; Belló-Klein A; Sander da Rosa Araujo A
J Cardiovasc Pharmacol; 2024 Jun; 83(6):612-620. PubMed ID: 38547510
[TBL] [Abstract][Full Text] [Related]
5. Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension.
Mendes-Ferreira P; Maia-Rocha C; Adão R; Mendes MJ; Santos-Ribeiro D; Alves BS; Cerqueira RJ; Castro-Chaves P; Lourenço AP; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
Cardiovasc Res; 2016 Jan; 109(1):44-54. PubMed ID: 26503987
[TBL] [Abstract][Full Text] [Related]
6. Colchicine Depolymerizes Microtubules, Increases Junctophilin-2, and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension.
Prins KW; Tian L; Wu D; Thenappan T; Metzger JM; Archer SL
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28566298
[TBL] [Abstract][Full Text] [Related]
7. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
[TBL] [Abstract][Full Text] [Related]
8. 17β-estradiol preserves right ventricular function in rats with pulmonary arterial hypertension: an echocardiographic and histochemical study.
Wang YD; Li YD; Ding XY; Wu XP; Li C; Guo DC; Shi YP; Lu XZ
Int J Cardiovasc Imaging; 2019 Mar; 35(3):441-450. PubMed ID: 30350115
[TBL] [Abstract][Full Text] [Related]
9. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
10. Copaiba Oil Attenuates Right Ventricular Remodeling by Decreasing Myocardial Apoptotic Signaling in Monocrotaline-Induced Rats.
Campos-Carraro C; Turck P; de Lima-Seolin BG; Tavares AMV; Dos Santos Lacerda D; Corssac GB; Teixeira RB; Hickmann A; Llesuy S; da Rosa Araujo AS; Belló-Klein A
J Cardiovasc Pharmacol; 2018 Nov; 72(5):214-221. PubMed ID: 30212415
[TBL] [Abstract][Full Text] [Related]
11. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension.
Umar S; de Visser YP; Steendijk P; Schutte CI; Laghmani el H; Wagenaar GT; Bax WH; Mantikou E; Pijnappels DA; Atsma DE; Schalij MJ; van der Wall EE; van der Laarse A
Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1606-16. PubMed ID: 19783775
[TBL] [Abstract][Full Text] [Related]
12. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
Leong ZP; Hikasa Y
Vascul Pharmacol; 2018 Nov; 110():31-41. PubMed ID: 30071297
[TBL] [Abstract][Full Text] [Related]
13. PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure.
Nguyen QT; Nsaibia MJ; Sirois MG; Calderone A; Tardif JC; Fen Shi Y; Ruiz M; Daneault C; Gagnon L; Grouix B; Laurin P; Dupuis J
Cardiovasc Res; 2020 Jan; 116(1):171-182. PubMed ID: 30753422
[TBL] [Abstract][Full Text] [Related]
14. Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension: mitochondrial inhibition as driver of cardiac failure?
Balestra GM; Mik EG; Eerbeek O; Specht PA; van der Laarse WJ; Zuurbier CJ
Respir Res; 2015 Feb; 16(1):6. PubMed ID: 25645252
[TBL] [Abstract][Full Text] [Related]
15. Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.
Bruce E; Shenoy V; Rathinasabapathy A; Espejo A; Horowitz A; Oswalt A; Francis J; Nair A; Unger T; Raizada MK; Steckelings UM; Sumners C; Katovich MJ
Br J Pharmacol; 2015 May; 172(9):2219-31. PubMed ID: 25522140
[TBL] [Abstract][Full Text] [Related]
16. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
[TBL] [Abstract][Full Text] [Related]
17. Soluble guanylate cyclase stimulator, trans-4-methoxy-β-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
Gonzaga-Costa K; Vasconcelos-Silva AA; Rodrigues-Silva MJ; Rebouça CDSM; Duarte GP; Borges RS; Magalhães PJC; Lahlou S
Eur J Pharmacol; 2021 Apr; 897():173948. PubMed ID: 33609564
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
[TBL] [Abstract][Full Text] [Related]
19. Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension.
Lambert M; Boet A; Rucker-Martin C; Mendes-Ferreira P; Capuano V; Hatem S; Adão R; Brás-Silva C; Hautefort A; Michel JB; Dorfmuller P; Fadel E; Kotsimbos T; Price L; Jourdon P; Montani D; Humbert M; Perros F; Antigny F
Cardiovasc Res; 2018 May; 114(6):880-893. PubMed ID: 29360952
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA
J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
